Recommendation based on the findings from the Phase 3 QUASAR programme in ulcerative colitis 1. Beerse, Belgium (28 February 2025) - Johnson & Johnson today announced that the Com ...

Johnson & Johnson (J&J) has shared positive results from a late-stage study evaluating a subcutaneous (SC) version of Tremfya ...

Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate to severe UC patients.

Tremfya (guselkumab) is a brand-name drug approved to treat ulcerative colitis (UC). This article covers topics such as side effects, dosage, and how Tremfya works. Tremfya is available as a ...

J&J announces positive data from phase 3 ASTRO study of Tremfya SC induction therapy in adults with moderately to severely active ulcerative colitis: Spring House, Pennsylvania Mo ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

Johnson & Johnson (NYSE: JNJ) announced significant advancements in the treatment of moderately to severely active ulcerative colitis (UC) with its drug TREMFYA® (guselkumab). The Phase 3 ASTRO ...

SPRING HOUSE, Pa. - Johnson & Johnson (NYSE: JNJ (NYSE:JNJ)) announced significant advancements in the treatment of moderately to severely active ulcerative colitis (UC) with its drug TREMFYA® ...